Company / Revenue per Share
Ultragenyx Pharmaceutical Inc. Revenue per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$7.28
FY2025
5-year range
$1.55 / $7.28
FY2021-FY2025
Trend
+6.9%
vs FY2024
Sector context
#56 of 154
Health Care
What the data says
At $7.28, Ultragenyx Pharmaceutical Inc.'s revenue per share ranks #56 of 154 in the Health Care sector. Revenue per Share has increased for 6 consecutive years, from $0.05 in FY2019 to $7.28 in FY2025.
Based on SEC 10-K filings.
7.28 in FY2025 with a 5-year CAGR of +52.2%.
Improved from $6.18 to $7.28 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +11.6%
- 5-Year CAGR
- +52.2%
- 10-Year CAGR
- -
Sector benchmark
#56 of 154 in Health CareTop 36% of 154This company $7.28 Sector average $15.09
▼
-51.8% below sector average
Key checks
Key Insights
- Ultragenyx Pharmaceutical Inc.'s revenue per share has grown for 6 consecutive years.
- In FY2025, revenue per share increased 6.9% year-over-year.
- Ranks #56 out of 154 companies in the Health Care sector.
- Lowest revenue per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.28 | +6.9% |
| FY2024 | $6.80 | +10.0% |
| FY2023 | $6.18 | +18.0% |
| FY2022 | $5.24 | +237.6% |
| FY2021 | $1.55 | +74.3% |
| FY2020 | $0.89 | +1633.6% |
| FY2019 | $0.05 | -95.6% |
| FY2018 | $1.17 | +36052.3% |
| FY2017 | $0.00 | +637.6% |
| FY2016 | $0.00 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026